< 1 minute read
Nov. 26, 2021

Milvexian: An Oral Factor XIa Inhibitor,


selective factor Xia serine protease inhib. oral, phase II, cardiovascular from opt. of previous macrocyclic FXIa inh. Journal of Medicinal Chemistry Bristol Myers Squibb

Drug Hunter Team

The BMS factor XIa inhibitor, milvexian (BMS-986177), is an oral antithrombotic with a Ki of 0.11 nM. A member of this macrocyclic series was previously highlighted as one of 2020’s Molecules of the Year . Poor pharmaceutic properties from previous preclinical molecules such as solubility were addressed resulting in this candidate. Milvexian [...]



Other molecules you may be interested in